通过ELOVL2调节的AR稳定有助于前列腺癌中酶胺耐药性
Jinpeng Cen1, Jiading Guo2, Xianzi Zeng3
1Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Frontiers in cell and developmental biology
|June 24, 2025
概括
向ELOVL2通过稳定雄激素受体 (AR) 信号,克服了割抵抗性前列腺癌 (CRPC) 中的酶胺耐药性. 抑制ELOVL2恢复了酶胺的敏感性,为CRPC患者提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 恩扎胺耐药性是治疗割耐性前列腺癌 (CRPC) 的一个主要挑战.
- 了解抵抗的分子机制对于开发有效疗法至关重要.
研究的目的:
- 调查CRPC中恩扎拉胺耐药性的分子机制.
- 探索针对这些机制的治疗策略,特别关注ELOVL2.
主要方法:
- 对LNCaP/胺胺耐药细胞进行了全面的生物信息分析.
- 通过向抑制超长链脂肪酸蛋白2 (ELOVL2) 的延长的功能验证.
- 评估癌细胞增殖,胺胺敏感性,以及对无素蛋白酶体系统和AR信号传递的影响.
主要成果:
- 提升ELOVL2的调节和脂肪酸代谢的激活是前列腺癌 (PCa) 酶胺耐药性的关键驱动因素.
- 针对ELOVL2的制抑制了增殖,并在耐药细胞中恢复了对胺酶的敏感性.
- ELOVL2 损害了无素-蛋白酶体系统,导致AR信号激活和酶胺耐药性.
结论:
- ELOVL2通过抑制其降解来稳定AR,从而促进CRPC中的酶胺耐药性.
- 向ELOVL2是一种有前途的治疗策略,可以克服CRPC中的酶胺耐药性.
- 这种方法有可能改善CRPC患者的临床结果.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Unfolded Protein Response
5.1K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228


